Entering text into the input field will update the search result below
Create free account
Search for Symbols, analysts, keywords
Log in
RMD
ResMed Inc.
Latest News
Follow
$198.00
1.67 (+0.85%)
9:34 AM 03/28/24
NYSE |
$USD |
Realtime
Summary
Ratings
Financials
Earnings
Dividends
Valuation
Growth
Profitability
Momentum
Peers
Options
Charting
All
Analysis
Comments
News
Transcripts
SEC Filings
Press Releases
Related Analysis
RMD News
Show Full Stories
Show Full Stories
This feature available only for pro users
Type:
All Types
Date Range:
Select Date
UBS sees Lilly GLP-1/sleep apnea study falling short of Street estimates
KeyBanc picks Inspire, Integer, ICU Medical as top medtech ideas
ResMed positive as Philips halts sales of sleep therapy devices
ResMed declares $0.48 dividend
ResMed jumps 9% as quarterly results shine
ResMed Non-GAAP EPS of $1.88 beats by $0.10, revenue of $1.2B beats by $50M
ResMed Q2 2024 Earnings Preview
ResMed product recall classified as most serious by FDA (update)
ResMed masks to remain on market despite recall: report
ResMed alerts customers to potential magnetic interference from masks
ResMed secures victory in patent fight against New York University
ResMed issues urgent safety notice over magnetic CPAP masks
M&A, GLP-1s to dominate healthcare themes in 2024 as COVID fades: survey
Goldman Sachs 2024 stock strategy - high quality
ResMed president & COO Rob Douglas to retire amid several executive moves
ResMed declares $0.48 dividend
ResMed stock declines after hours on FQ1 revenue miss, gross margin contraction
ResMed Non-GAAP EPS of $1.64 beats by $0.02, revenue of $1.1B misses by $10M
ResMed Q1 2024 Earnings Preview
FDA forms advisory committee to regulate digital health
ResMed upgraded at JPMorgan; says GLP-1 threat overdone
BofA’s Alpha Surprise Model: Lots of Energy additions, Consumer Discretionary deletions
ResMed slips as Wolfe downgrades citing a balanced outlook
JPMorgan says time to buy MedTech based on past
ResMed goes ex dividend tomorrow
ResMed hits 52-week low after Q4 miss
ResMed Non-GAAP EPS of $1.60 misses by $0.09, revenue of $1.12B misses by $20M
ResMed FQ4 2023 Earnings Preview
ResMed upgraded at RBC Capital Markets ahead of Q4 earnings
ResMed buys privately-held Somnoware
Morgan Stanley sees broader MedTech impact from weight loss drugs
ResMed sees top and bottom line Q1 beats on strong demand for sleep devices
ResMed Non-GAAP EPS of $1.68 beats by $0.09, revenue of $1.12B beats by $70M
ResMed Q3 2023 Earnings Preview
Stocks that thrive and struggle the most as rates rise - BofA
Pharmas, medtechs dominate list of innovation leaders thanks to patents
ResMed goes ex dividend tomorrow
Merck, GM among BofA's latest Alpha Surprise picks
ResMed appoints CEO Michael Farrell as chair of the board
ResMed Non-GAAP EPS of $1.66 beats by $0.04, revenue of $1.03B beats by $33.78M
1
2
3
4
5
Next
People Also Follow
Similar to RMD
ETFs Holding RMD
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.